Log in

2511 Hightide Therapeutics Inc HKEX · China

Hightide Therapeutics (2511) news

Hightide Therapeutics Inc is a public biotech or pharmaceutical company listed on HKEX under the ticker 2511, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Hightide Therapeutics news

We have not published a story on Hightide Therapeutics yet. When there is news, it will appear here.

Questions about Hightide Therapeutics

What is the ticker symbol of Hightide Therapeutics?

Hightide Therapeutics Inc trades under the ticker 2511 on HKEX.

Where is Hightide Therapeutics listed?

Hightide Therapeutics Inc is listed on HKEX.

Which country or territory is Hightide Therapeutics listed under?

Our directory records Hightide Therapeutics Inc under China.

What does Hightide Therapeutics do?

Our directory classifies Hightide Therapeutics Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Hightide Therapeutics?

The ISIN recorded for Hightide Therapeutics Inc is KYG4568L1023.

Does aibio.space cover Hightide Therapeutics?

aibio.space lists Hightide Therapeutics Inc among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Hightide Therapeutics?

Companies in our directory listed in the same country and business area as Hightide Therapeutics: Jiangsu Jibeier Pharmaceutical Co., Nanjing Hicin Pharmaceutical Co., CASI Pharmaceuticals, Sunflower Pharmaceutical Group Co., Consun Pharmaceutical Group, Tianjin Chase Sun Pharmaceutical Co..

Investor discussion: Hightide Therapeutics

Members talk about Hightide Therapeutics (2511). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Hightide Therapeutics, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

  2. Financings

    Share or debt issue: PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

  3. Financings

    Share or debt issue: (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED RE-APPOINTMENT OF AUDITOR; (3) PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES, RESELL TREASURY SHARES AND REPURCHASE SHARES; AND (4) NOTICE OF ANNUAL GENERAL MEETING. Source

  4. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

  5. Financings

    Share or debt issue: PLACING OF NEW SHARES UNDER GENERAL MANDATE. Source

  6. Financings

    Share or debt issue: (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED RE-APPOINTMENT OF AUDITOR; (3) PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES, RESELL TREASURY SHARES AND REPURCHASE SHARES; (4) PROPOSED ADOPTION OF 2025 SHARE INCENTIVE PLAN AND (5) NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Hightide Therapeutics's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    GRANTS OF OPTIONS AND AWARDS

  2. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  3. HKEXnews

    COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

  4. HKEXnews

    PLACING OF NEW SHARES UNDER GENERAL MANDATE

  5. HKEXnews

    VOLUNTARY ANNOUNCEMENT LATEST BUSINESS UPDATE OF THE GROUP

  6. HKEXnews

    UPDATE ON CONNECTED TRANSACTION TERMINATION OF THE LOAN AGREEMENT

  7. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 29, 2026

  8. HKEXnews

    NOTICE OF ANNUAL GENERAL MEETING

  9. HKEXnews

    (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED RE-APPOINTMENT OF AUDITOR; (3) PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES, RESELL TREASURY SHARES AND REPURCHASE SHARES; AND (4) NOTICE OF ANNUAL GENERAL MEETING

  10. HKEXnews

    CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGES IN COMPOSITION OF BOARD COMMITTEES

  11. HKEXnews

    CONNECTED TRANSACTION THE LOAN AGREEMENT

  12. HKEXnews

    (REVISED TITLE) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND CHANGE IN USE OF PROCEEDS

  13. HKEXnews

    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

  14. HKEXnews

    HIGHTIDE THERAPEUTICS ANNOUNCES ACCEPTANCE OF NEW DRUG APPLICATION FOR HTD1801 BY CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION

  15. HKEXnews

    HIGHTIDE THERAPEUTICS ANNOUNCES COMPLETION OF PHASE IIB CLINICAL STUDY OF HTD1801 FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)

  16. HKEXnews

    HIGHTIDE THERAPEUTICS APPOINTS DR. FILIP SURMONT AS CMO TO ADVANCE THE DEVELOPMENT OF CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME PORTFOLIO

  17. HKEXnews

    TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE

  18. HKEXnews

    HIGHTIDE THERAPEUTICS' HTD1801 ACHIEVES GREATER HBA1C REDUCTION AND SUPERIOR CARDIOMETABOLIC MARKER IMPROVEMENT VERSUS DAPAGLIFLOZIN IN PHASE III HEAD-TO-HEAD TRIAL

  19. HKEXnews

    LATE-BREAKING ASN 2025 | HIGHTIDE THERAPEUTICS PRESENTS EVIDENCE OF RENAL BENEFIT WITH HTD1801

  20. HKEXnews

    HTD1801, A FIRST-IN-CLASS ANTI-INFLAMMATORY METABOLIC MODULATOR, DEMONSTRATES DURABLE 52-WEEK EFFICACY AND SAFETY IN COMPLETION OF TWO PHASE III TRIALS IN TYPE 2 DIABETES MELLITUS

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2511 on TradingView.

Listing details

Hightide Therapeutics Inc is a public biotech or pharmaceutical company listed on HKEX under the ticker 2511, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Hightide Therapeutics Inc
Ticker
2511
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
KYG4568L1023
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.